The American Medical Association (AMA) has expressed approval for the recent Supreme Court decision that maintains access to mifepristone, a medication used in reproductive care. The ruling comes amid ongoing debates and legal challenges concerning the drug's availability.

In previous statements, the AMA has consistently opposed measures that restrict access to mifepristone. In August 2023, the organization condemned court rulings that "chip away at mifepristone access," describing such decisions as detrimental to patient care. Similarly, in April 2023, the AMA characterized restored restrictions on the medication as "a step backwards" and criticized a Texas ruling against mifepristone, stating it "flies in the face of science."

The AMA has long advocated for lifting restrictions on reproductive care medications. In April 2021, they praised actions that removed limitations on such drugs.

The organization's viewpoints highlight concerns about patient harm due to reduced access to mifepristone and argue that judicial decisions limiting its use lack a basis in medical science.

Additionally, the AMA has filed an amicus brief in support of maintaining access to mifepristone in the case Alliance for Hippocratic Medicine v. FDA.